Today: 7 February 2026
Subscribe
Browse Category

Earnings Reports News 12 January 2026

Palantir stock gets a Citi upgrade — and a Feb. 2 earnings date — why PLTR is moving now

Palantir stock gets a Citi upgrade — and a Feb. 2 earnings date — why PLTR is moving now

Palantir shares rose about 1.1% in after-hours trading after Citi upgraded the stock to “Buy” and raised its price target, citing stronger demand for AI tools. The company will report fourth-quarter and full-year earnings on Feb. 2. Palantir closed at $179.41 Monday, after swinging between $174.03 and $182.48 during the session. ARK Invest trimmed its stake by selling 58,741 shares.
12 January 2026
··
Broadcom (AVGO) stock rises after the bell as ARK buys in — CPI and chip earnings loom

Broadcom (AVGO) stock rises after the bell as ARK buys in — CPI and chip earnings loom

Broadcom shares rose 2.1% to $352.21 in after-hours trading Monday, following news that ARK Invest bought 31,573 shares valued at about $10.5 million. CEO Hock Tan projects AI chip revenue to double to $8.2 billion this quarter, but the company warned of margin pressure from lower-margin custom AI processors. The stock remains 15% below its December peak. Investors await U.S. inflation data Tuesday and TSMC results Thursday.
12 January 2026
···
Microsoft stock slips after the bell as Goldman flags “compounding AI cycles” ahead of earnings

Microsoft stock slips after the bell as Goldman flags “compounding AI cycles” ahead of earnings

Microsoft shares slipped 0.4% after hours Monday to $477.22. Goldman Sachs resumed coverage with a Buy rating and raised its price target to $655, while Barclays trimmed its target to $610. Investors are watching Tuesday’s U.S. CPI report and Microsoft’s Jan. 28 earnings release. Societe Generale will switch to Microsoft’s Copilot AI tool, according to Bloomberg.
12 January 2026
····
Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam shares fell 6.7% to $370.91 in after-hours trading Monday after the company issued 2026 sales guidance and launched its “Alnylam 2030” plan. Preliminary Q4 sales of Amvuttra reached about $827 million, missing some estimates. Management projected 2026 net product revenue of $4.9–$5.3 billion, mostly from its TTR franchise. The company targets over 25% annual revenue growth through 2030.
12 January 2026
···
Tesla stock edges up after hours as robotaxi deadlines, CPI and earnings line up as next tests for TSLA

Tesla stock edges up after hours as robotaxi deadlines, CPI and earnings line up as next tests for TSLA

Tesla shares rose 0.9% to $448.90 in late Monday trading after a report outlined new 2026 plans including robotaxis and the “Cybercab.” More than 61 million shares traded as the S&P 500 and Dow hit record closes. Investors await Tuesday’s U.S. inflation data and Tesla’s Jan. 28 earnings report. Tesla’s annual sales recently fell for a second year, with China’s BYD now the top EV seller.
12 January 2026
···
iRhythm (IRTC) stock drops after JPM update points to $880 million 2026 revenue

iRhythm (IRTC) stock drops after JPM update points to $880 million 2026 revenue

iRhythm shares fell 5.6% to $169.30 in late trading Monday after the company forecast 2026 revenue of $870–$880 million and an adjusted EBITDA margin of 11.5%–12.5%. Investors focused on the lack of detailed cost and margin data, as well as an upcoming corporate name change. About 1.35 million shares traded, with the stock swinging between $157.34 and $179.82. The company’s update remains preliminary.
12 January 2026
··
Lowe’s stock edges higher while Home Depot slips; traders eye Feb. 25 earnings call

Lowe’s stock edges higher while Home Depot slips; traders eye Feb. 25 earnings call

Lowe’s shares rose 1.1% to $270.09 Monday afternoon, outpacing Home Depot, which slipped 0.6%. About 1.9 million Lowe’s shares changed hands as Wall Street steadied after an early dip tied to Fed concerns. Lowe’s next earnings call is set for Feb. 25, with a $1.20 dividend payable Feb. 4 to holders on record Jan. 21. The stock moved within a $263.83–$270.98 range during the session.
12 January 2026
···
Urban Outfitters stock slides despite “record” holiday sales — what spooked URBN shares

Urban Outfitters stock slides despite “record” holiday sales — what spooked URBN shares

Urban Outfitters shares fell 12% after hours Monday despite a 9% rise in holiday sales, as investors worried about profit margins and future demand. The stock touched $70.27 before recovering to $71.49. Apparel stocks broadly declined after weak forecasts from Abercrombie & Fitch and Birkenstock. Urban Outfitters opened 58 new stores and closed seven in the past eleven months.
12 January 2026
··
HealthEquity stock slides nearly 10% after 2027 outlook; JPM conference is next test

HealthEquity stock slides nearly 10% after 2027 outlook; JPM conference is next test

HealthEquity shares fell about 10% Monday after the company issued a cautious initial fiscal 2027 outlook, projecting revenue between $1.38 billion and $1.41 billion and an HSA cash yield near 3.75%. The stock last traded at $84.62, down $9.53. Executives will present at the J.P. Morgan Healthcare Conference on Tuesday. The company reaffirmed its 2026 guidance.
12 January 2026
··
Texas Instruments stock slips as chip ETF firms; investors eye Jan. 27 earnings amid Fed jitters

Texas Instruments stock slips as chip ETF firms; investors eye Jan. 27 earnings amid Fed jitters

Texas Instruments shares slipped 0.2% to $189.85 in Monday afternoon trading, underperforming chip sector peers as the iShares Semiconductor ETF rose 0.7% and Nvidia gained about 1%. Investors are watching TI’s Jan. 27 earnings for signals on industrial and auto demand amid market volatility tied to a Justice Department probe involving Fed Chair Jerome Powell.
12 January 2026
····
Lululemon stock rises after holiday-quarter outlook shifts to high end as LULU investors eye ICR

Lululemon stock rises after holiday-quarter outlook shifts to high end as LULU investors eye ICR

Lululemon shares rose 3.2% to $210.43 Monday after the company said holiday-quarter revenue and profit would reach the high end of its forecast, citing strong seasonal demand. The retailer maintained its margin and expense outlook. CEO Calvin McDonald steps down Jan. 31, with interim co-CEOs named as the board searches for a replacement. Founder Chip Wilson has launched a proxy fight as Elliott Management builds a $1 billion stake.
12 January 2026
··
Honeywell stock flat as new Google Cloud retail tech lands, Citi trims target ahead of earnings

Honeywell stock flat as new Google Cloud retail tech lands, Citi trims target ahead of earnings

Honeywell shares edged up 0.1% to $207.50 after launching new software tools for retail and warehouse operations. Citi lowered its price target to $262 but maintained a buy rating. Investors await Honeywell’s Jan. 29 results and 2026 outlook for signs of demand and margin trends. Honeywell will start rolling out its new Smart Shopping Platform in February.
12 January 2026
··
Lemonade stock hits fresh 52-week high as LMND rallies; traders watch short interest and earnings

Lemonade stock hits fresh 52-week high as LMND rallies; traders watch short interest and earnings

Lemonade shares jumped 7.7% to $85.81 Monday, hitting a new 52-week high amid heavy short interest and volatile trading. About 20% of the float was shorted as of mid-December, raising the risk of sharp moves. Chief insurance officer John Peters sold 10,000 shares Jan. 6 at $80 under a pre-set plan. The next earnings report is expected Feb. 24.
12 January 2026
··
Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio shares fell 17.7% to $6.62 Monday after announcing a licensing deal with Eisai and releasing initial sales data for its lung-cancer drug. Eisai will pay €50 million upfront for rights outside the U.S., China, and Japan, with further milestone payments possible. Fourth-quarter Ibtrozi sales met estimates, but investors appeared cautious on future prescription growth.
12 January 2026
····
Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Johnson & Johnson shares rose 2.3% to $209.03 after new data showed its drug Rybrevant, combined with chemotherapy, produced a 51% response rate in metastatic colorectal cancer. The results, from the OrigAMI-1 trial, included a 73% response rate in first-line patients. The company’s fourth-quarter earnings report is due Jan. 21. J&J recently struck a deal with the Trump administration to lower U.S. drug prices.
12 January 2026
···
Procter & Gamble stock rises as defensive staples rally on Powell probe; PG earnings ahead

Procter & Gamble stock rises as defensive staples rally on Powell probe; PG earnings ahead

Procter & Gamble shares rose about 1% to $143.29 Monday afternoon, outpacing the S&P 500’s 0.2% gain as consumer-staples stocks advanced. The move came amid renewed market volatility after news broke of a criminal probe into Fed Chair Jerome Powell. Investors are watching U.S. inflation data and P&G’s Jan. 22 earnings report for further direction.
12 January 2026
··
1 … 94 95 96 97 98 … 203

Stock Market Today

AMD stock rebounds 8% after post-earnings slump as payrolls, CPI loom

AMD stock rebounds 8% after post-earnings slump as payrolls, CPI loom

7 February 2026
AMD shares jumped 8.2% to $208.44 Friday, rebounding after a 13% plunge earlier in the week on weak guidance and AI competition fears. The Philadelphia semiconductor index rose 5.7% as chip stocks led a broader market rally. Investors are awaiting next week’s U.S. payrolls and inflation data, which could shift rate expectations for tech.
Netflix stock price ends higher as DOJ widens review of Warner deal — what to watch next week

Netflix stock price ends higher as DOJ widens review of Warner deal — what to watch next week

7 February 2026
Netflix shares rose 1.6% to $82.20 Friday as the Justice Department expanded its antitrust review of the company’s planned $82.7 billion Warner Bros Discovery acquisition. A Wall Street Journal report said investigators are probing possible anti-competitive tactics. Director Reed Hastings reported a transfer of 241,944 shares via a family trust, according to an SEC filing.
Go toTop